Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1167 in Alzheimer's Disease patients on donepezil
NCT06285240Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-1167 in Alzheimer's disease (AD) (4 arms), sponsored by Merck & Co. Primary endpoints: Adverse Event at 7 weeks and Adverse Event Leading to Discontinuation at 4 weeks. Started Mar 2024; status: completed.
02
Drugs
MK-1167
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06285240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285240.